Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Drug Profile

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Alternative Names: MK-7123; PS-291822; SCH 527123; SCH 5271234

Latest Information Update: 03 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacopeia; Schering-Plough
  • Developer Ligand Pharmaceuticals; Merck & Co
  • Class Anti-inflammatories; Benzamides; Cyclobutanes
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Apr 2018 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Israel (PO) (NCT03473925)
  • 22 Mar 2018 Merck & Co. plans a phase II trial of navarixin in combination with pembrolizumab for Solid tumours (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) (NCT03473925)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top